博拓生物20260119

Summary of the Conference Call for Botao Bio Company Overview - Company: Botao Bio - Industry: Brain-Computer Interface (BCI) and In Vitro Diagnostics (IVD) Key Points Strategic Positioning in Brain-Computer Interface - Botao Bio views the brain-computer interface sector as a second growth curve and has invested in two companies: Qingshi Yongjun (invasive) and Haoshi Tianhui (non-invasive) to cover different technological paths for depression treatment [2][4] - Haoshi Tianhui focuses on non-invasive BCI combined with AI technology, capable of assessing depression or anxiety in 90 seconds and providing personalized music therapy, currently applied in hospitals and schools, with Botao holding a 16% stake [2][6] - Qingshi Yongjun specializes in invasive BCI for treatment-resistant depression, currently conducting clinical trials with significant results from the first patient treated with deep brain stimulation (DBS) [2][7] Clinical Trials and Progress - The first patient in the invasive BCI clinical trial has been followed for nearly five years without relapse, indicating long-term efficacy [2][11] - A new round of clinical trials started in June 2025, with 4 patients enrolled so far, and plans to enroll 100 patients by the end of 2026 [2][12] Financial and Investment Plans - Botao Bio plans to increase its stake in Qingshi Yongjun to over 10% by the end of 2026 to support formal clinical registration and related costs [2][14] - The company maintains a strong cash flow and is actively seeking suitable projects for investment in the healthcare sector to drive innovation and commercialization [3][9] Market Potential and Product Development - The global market for depression treatment is substantial, with approximately 300 million patients worldwide, including 95 million in China [7] - Botao Bio has developed a personalized depression brain network technology that is considered leading both domestically and globally [10] Future Expansion Plans - The company aims to expand its BCI strategy beyond current projects to include other indications such as Parkinson's and epilepsy [8] - Botao Bio is committed to deepening its industrial cooperation in the BCI field, supported by national policies and local government collaboration [19] Collaborations and Partnerships - Botao Bio's collaboration with Qingshi Yongjun is positioned as a strategic investment rather than a financial one, focusing on registration systems and market channels, particularly in domestic and international markets [20] - The company also plans to collaborate with Haoshi Tianhui in sales, production, and registration [20] New Product Developments - Botao Bio is advancing new products in the microfluidics technology sector, which are gradually obtaining certifications and being promoted in the market [21] - The company expects significant milestones in 2026, including progress in microfluidic product certifications and further developments in the BCI field [22]